Article

Key clinical point: Tralokinumab was well tolerated and maintained long-term disease control for up to 2 years in patients with moderate-to-severe atopic dermatitis (AD).

 Major finding: In the safety analysis set (n = 1174), the exposure-adjusted incidence rate of adverse events (AE) was 237.8 events/100 patient-years of exposure and 71.9% of participants reported ≥1 AE of mostly mild or moderate severity. In the efficacy analysis set (n = 345), 82.5% of patients treated with tralokinumab for 2 years maintained ≥75% improvement in the Eczema Area and Severity Index.

Study details: Findings are from the 2-year post hoc interim analysis of the ongoing, 5-year open-label extension trial, ECZTEND, including adult participants with moderate-to-severe AD from previous parent trials who received 300 mg tralokinumab every 2 weeks with or without topical corticosteroids.

Disclosures: The ECZTEND trial was sponsored by LEO Pharma A/S. Three authors declared being employees of LEO Pharma, and other authors reported ties with several sources, including LEO Pharma.

Source: Blauvelt A et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022 (Jul 18). Doi: 10.1016/j.jaad.2022.07.019

Key clinical point: Tralokinumab was well tolerated and maintained long-term disease control for up to 2 years in patients with moderate-to-severe atopic dermatitis (AD).

 Major finding: In the safety analysis set (n = 1174), the exposure-adjusted incidence rate of adverse events (AE) was 237.8 events/100 patient-years of exposure and 71.9% of participants reported ≥1 AE of mostly mild or moderate severity. In the efficacy analysis set (n = 345), 82.5% of patients treated with tralokinumab for 2 years maintained ≥75% improvement in the Eczema Area and Severity Index.

Study details: Findings are from the 2-year post hoc interim analysis of the ongoing, 5-year open-label extension trial, ECZTEND, including adult participants with moderate-to-severe AD from previous parent trials who received 300 mg tralokinumab every 2 weeks with or without topical corticosteroids.

Disclosures: The ECZTEND trial was sponsored by LEO Pharma A/S. Three authors declared being employees of LEO Pharma, and other authors reported ties with several sources, including LEO Pharma.

Source: Blauvelt A et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022 (Jul 18). Doi: 10.1016/j.jaad.2022.07.019

Key clinical point: Tralokinumab was well tolerated and maintained long-term disease control for up to 2 years in patients with moderate-to-severe atopic dermatitis (AD).

 Major finding: In the safety analysis set (n = 1174), the exposure-adjusted incidence rate of adverse events (AE) was 237.8 events/100 patient-years of exposure and 71.9% of participants reported ≥1 AE of mostly mild or moderate severity. In the efficacy analysis set (n = 345), 82.5% of patients treated with tralokinumab for 2 years maintained ≥75% improvement in the Eczema Area and Severity Index.

Study details: Findings are from the 2-year post hoc interim analysis of the ongoing, 5-year open-label extension trial, ECZTEND, including adult participants with moderate-to-severe AD from previous parent trials who received 300 mg tralokinumab every 2 weeks with or without topical corticosteroids.

Disclosures: The ECZTEND trial was sponsored by LEO Pharma A/S. Three authors declared being employees of LEO Pharma, and other authors reported ties with several sources, including LEO Pharma.

Source: Blauvelt A et al. Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial. J Am Acad Dermatol. 2022 (Jul 18). Doi: 10.1016/j.jaad.2022.07.019

Key clinical point: Abrocitinib was more effective than dupilumab in inducing early itch reduction and controlling disease severity in adults with moderate-to-severe atopic dermatitis (AD) on background topical therapy.

Major finding: A significantly higher proportion of patients in the abrocitinib vs dupilumab group achieved ≥4-point improvement in the Peak Pruritus Numerical Rating Scale score at week 2 (48% vs 26%; P < .0001) and ≥90% improvement in the Eczema Area and Severity Index at week 4 (29% vs 15%; P < .0001). Treatment-emergent adverse events were more frequent in the abrocitinib vs dupilumab group (74% vs 65%).

Study details: Findings are from a phase 3 trial including 727 adults with moderate-to-severe AD who showed inadequate response to medicated topical therapy and were randomly assigned to receive oral abrocitinib or subcutaneous dupilumab for 26 weeks.

Disclosures: This study was funded by Pfizer. Seven authors declared being current or former employees or shareholders of Pfizer or Pfizer Pharma. The other authors reported ties with several sources.

Source: Reich K et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273-282 (Jul 23). Doi: 10.1016/S0140-6736(22)01199-0

Key clinical point: Abrocitinib was more effective than dupilumab in inducing early itch reduction and controlling disease severity in adults with moderate-to-severe atopic dermatitis (AD) on background topical therapy.

Major finding: A significantly higher proportion of patients in the abrocitinib vs dupilumab group achieved ≥4-point improvement in the Peak Pruritus Numerical Rating Scale score at week 2 (48% vs 26%; P < .0001) and ≥90% improvement in the Eczema Area and Severity Index at week 4 (29% vs 15%; P < .0001). Treatment-emergent adverse events were more frequent in the abrocitinib vs dupilumab group (74% vs 65%).

Study details: Findings are from a phase 3 trial including 727 adults with moderate-to-severe AD who showed inadequate response to medicated topical therapy and were randomly assigned to receive oral abrocitinib or subcutaneous dupilumab for 26 weeks.

Disclosures: This study was funded by Pfizer. Seven authors declared being current or former employees or shareholders of Pfizer or Pfizer Pharma. The other authors reported ties with several sources.

Source: Reich K et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273-282 (Jul 23). Doi: 10.1016/S0140-6736(22)01199-0

Key clinical point: Abrocitinib was more effective than dupilumab in inducing early itch reduction and controlling disease severity in adults with moderate-to-severe atopic dermatitis (AD) on background topical therapy.

Major finding: A significantly higher proportion of patients in the abrocitinib vs dupilumab group achieved ≥4-point improvement in the Peak Pruritus Numerical Rating Scale score at week 2 (48% vs 26%; P < .0001) and ≥90% improvement in the Eczema Area and Severity Index at week 4 (29% vs 15%; P < .0001). Treatment-emergent adverse events were more frequent in the abrocitinib vs dupilumab group (74% vs 65%).

Study details: Findings are from a phase 3 trial including 727 adults with moderate-to-severe AD who showed inadequate response to medicated topical therapy and were randomly assigned to receive oral abrocitinib or subcutaneous dupilumab for 26 weeks.

Disclosures: This study was funded by Pfizer. Seven authors declared being current or former employees or shareholders of Pfizer or Pfizer Pharma. The other authors reported ties with several sources.

Source: Reich K et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273-282 (Jul 23). Doi: 10.1016/S0140-6736(22)01199-0

Key clinical point: Compared with circulating tumor DNA (ctDNA)-negative patients, ctDNA-positive patients are at a higher risk for recurrence and have a poorer prognosis for recurrence-free survival (RFS) after colorectal cancer (CRC) surgery and adjuvant chemotherapy (ACT).

Major finding: After CRC surgery and ACT, ctDNA-positive vs -negative patients were at a higher risk for CRC recurrence (relative risk [RR] 4.43 and RR 5.77, respectively; both P < .05) and had a worse prognosis for RFS (adjusted hazard ratio, 10.74 and adjusted RR 22.09, respectively; both P < .05).

Study details: This was a meta-analysis of 14 studies including 2393 patients who underwent radical R0 resection for primary CRC.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Mi J et al. Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta-analysis. Eur J Clin Invest. 2022 (Jul 20). Doi: 10.1111/eci.13842

Key clinical point: Compared with circulating tumor DNA (ctDNA)-negative patients, ctDNA-positive patients are at a higher risk for recurrence and have a poorer prognosis for recurrence-free survival (RFS) after colorectal cancer (CRC) surgery and adjuvant chemotherapy (ACT).

Major finding: After CRC surgery and ACT, ctDNA-positive vs -negative patients were at a higher risk for CRC recurrence (relative risk [RR] 4.43 and RR 5.77, respectively; both P < .05) and had a worse prognosis for RFS (adjusted hazard ratio, 10.74 and adjusted RR 22.09, respectively; both P < .05).

Study details: This was a meta-analysis of 14 studies including 2393 patients who underwent radical R0 resection for primary CRC.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Mi J et al. Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta-analysis. Eur J Clin Invest. 2022 (Jul 20). Doi: 10.1111/eci.13842

Key clinical point: Compared with circulating tumor DNA (ctDNA)-negative patients, ctDNA-positive patients are at a higher risk for recurrence and have a poorer prognosis for recurrence-free survival (RFS) after colorectal cancer (CRC) surgery and adjuvant chemotherapy (ACT).

Major finding: After CRC surgery and ACT, ctDNA-positive vs -negative patients were at a higher risk for CRC recurrence (relative risk [RR] 4.43 and RR 5.77, respectively; both P < .05) and had a worse prognosis for RFS (adjusted hazard ratio, 10.74 and adjusted RR 22.09, respectively; both P < .05).

Study details: This was a meta-analysis of 14 studies including 2393 patients who underwent radical R0 resection for primary CRC.

Disclosures: The study did not receive any funding. The authors declared no conflicts of interest.

Source: Mi J et al. Circulation tumour DNA in predicting recurrence and prognosis in operable colorectal cancer patients: A meta-analysis. Eur J Clin Invest. 2022 (Jul 20). Doi: 10.1111/eci.13842

Key clinical point: After considering time-related biases such as immortal time bias (ITB), metformin use is nonsignificantly associated with subsequent colorectal cancer (CRC) incidence in patients with type‑2 diabetes (T2D).

Major finding: Time-dependent Cox regression, landmark, or nested case-control analysis did not reveal a significant association between metformin use and CRC incidence, with hazard ratios (95% CI) for metformin ever-use (≥90 days of metformin prescription throughout follow-up) being 0.88 (0.68-1.13), 0.86 (0.65-1.12), and 1.10 (0.86-1.40), respectively, and those for average metformin prescription days/year being 0.97 (0.90-1.04), 0.95 (0.88-1.04), and 1.02 (0.95-1.10), respectively.

Study details: This observational study employed statistical methods that avoid ITB to analyze the real-world data of 41,533 patients newly diagnosed with T2D who were cancer-free at T2D diagnosis from a prospectively maintained cohort.

Disclosures: No source of funding was disclosed. The authors reported no conflicts of interest.

Source: Zhang HS et al. Metformin use is not associated with colorectal cancer incidence in type-2 diabetes patients: Evidence from methods that avoid immortal time bias. Int J Colorectal Dis. 2022;37:1827–1834 (Jul 14). Doi: 10.1007/s00384-022-04212-9

Key clinical point: After considering time-related biases such as immortal time bias (ITB), metformin use is nonsignificantly associated with subsequent colorectal cancer (CRC) incidence in patients with type‑2 diabetes (T2D).

Major finding: Time-dependent Cox regression, landmark, or nested case-control analysis did not reveal a significant association between metformin use and CRC incidence, with hazard ratios (95% CI) for metformin ever-use (≥90 days of metformin prescription throughout follow-up) being 0.88 (0.68-1.13), 0.86 (0.65-1.12), and 1.10 (0.86-1.40), respectively, and those for average metformin prescription days/year being 0.97 (0.90-1.04), 0.95 (0.88-1.04), and 1.02 (0.95-1.10), respectively.

Study details: This observational study employed statistical methods that avoid ITB to analyze the real-world data of 41,533 patients newly diagnosed with T2D who were cancer-free at T2D diagnosis from a prospectively maintained cohort.

Disclosures: No source of funding was disclosed. The authors reported no conflicts of interest.

Source: Zhang HS et al. Metformin use is not associated with colorectal cancer incidence in type-2 diabetes patients: Evidence from methods that avoid immortal time bias. Int J Colorectal Dis. 2022;37:1827–1834 (Jul 14). Doi: 10.1007/s00384-022-04212-9

Key clinical point: After considering time-related biases such as immortal time bias (ITB), metformin use is nonsignificantly associated with subsequent colorectal cancer (CRC) incidence in patients with type‑2 diabetes (T2D).

Major finding: Time-dependent Cox regression, landmark, or nested case-control analysis did not reveal a significant association between metformin use and CRC incidence, with hazard ratios (95% CI) for metformin ever-use (≥90 days of metformin prescription throughout follow-up) being 0.88 (0.68-1.13), 0.86 (0.65-1.12), and 1.10 (0.86-1.40), respectively, and those for average metformin prescription days/year being 0.97 (0.90-1.04), 0.95 (0.88-1.04), and 1.02 (0.95-1.10), respectively.

Study details: This observational study employed statistical methods that avoid ITB to analyze the real-world data of 41,533 patients newly diagnosed with T2D who were cancer-free at T2D diagnosis from a prospectively maintained cohort.

Disclosures: No source of funding was disclosed. The authors reported no conflicts of interest.

Source: Zhang HS et al. Metformin use is not associated with colorectal cancer incidence in type-2 diabetes patients: Evidence from methods that avoid immortal time bias. Int J Colorectal Dis. 2022;37:1827–1834 (Jul 14). Doi: 10.1007/s00384-022-04212-9

Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study.

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study.

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Key clinical point: The risk for all-cause mortality and cancer progression or death is lower among patients with metastatic colorectal cancer (CRC) and a higher intake of vegetable fats.

Major finding: Patients with the highest (23.5% kcal/day; interquartile range [IQR] 21.6%-25.7% kcal/day) vs lowest (11.6% kcal/day; IQR 10.1%-12.7% kcal/day) median intake of vegetable fats showed a lower risk for all-cause mortality (adjusted hazard ratio [aHR] 0.79; 95% CI 0.63-1.00) and cancer progression or death (aHR 0.71; 95% CI 0.57-0.88).

Study details: Findings are from a prospective analysis that included 1149 patients with metastatic CRC from the CALGB 80405 (Alliance)/SWOG 80405 study.

Disclosures: This study was supported by the US National Cancer Institute of the National Institutes of Health and partly by Bristol Myers Squibb, Genentech, Pfizer, and Sanofi. Some authors declared serving as advisory board members or consultants for or receiving research support or payments for research advice or services from various sources, including Pfizer and Genentech.

Source: Van Blarigan EL et al. Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: Data from CALGB 80405 (Alliance)/SWOG 80405. Int J Cancer. 2022 (Jul 29). Doi: 10.1002/ijc.34230

Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.

Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P  =  .006) and larger postoperative tumor diameters (7.26 vs 6.21; P  =  .033).

Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076

Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.

Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P  =  .006) and larger postoperative tumor diameters (7.26 vs 6.21; P  =  .033).

Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076

Key clinical point: Neoadjuvant chemotherapy (NCT) is associated with higher carcinoembryonic antigen (CEA) levels and multiorgan resection rates owing to larger postoperative tumor size in patients with mismatch repair deficient (dMMR) colon cancer.

Major finding: Patients who received vs did not receive NCT had a higher incidence of abnormal CEA levels (51.6% vs 17.4%; P < .001) and multiorgan resection rate (38.7% vs 16.8%; P  =  .006) and larger postoperative tumor diameters (7.26 vs 6.21; P  =  .033).

Study details: This retrospective study analyzed the data of 335 patients with dMMR colon cancer who did (n = 31) or did not (n = 304) receive neoadjuvant chemotherapy after radical surgery.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Yunlong W et al. The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency. Cancer Med. 2022 (Jul 29). Doi: 10.1002/cam4.5076

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022;72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022;72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Key clinical point: An increase in consultation rates for colorectal cancer (CRC)-relevant symptoms and abnormal blood test results in the 2-year prediagnosis period hint at early initiation of specific investigations or referrals, thereby accelerating the diagnosis and treatment in some patients with symptomatic CRC.

Major finding: The earliest clinical feature to show increased recording rate from the baseline was rectal bleeding, at 10 months before colon cancer diagnosis (95% CI 8.3-11.7) and 8 months before rectal cancer diagnosis (95% CI 6.1-9.9). The rate of abnormal blood measurements (low hemoglobin levels, high platelet counts, etc) recorded increased from 9 months prediagnosis.

Study details: Findings are from a retrospective study that analyzed linked primary care and cancer registry data of patients with colon (n = 5033) or rectal (2516) cancer.

Disclosures: This study was supported by the National Institute for Health Research School for Primary Care Research and linked to the CanTest Collaborative funded by Cancer Research UK. Four authors are a part of the CanTest Collaborative.

Source: Moullet M et al. Pre-diagnostic clinical features and blood tests in patients with colorectal cancer: a retrospective linked-data study. Br J Gen Pract. 2022;72(721):e556-e563 (Jul 28). Doi: 10.3399/BJGP.2021.0563

Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).

Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.

Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi:  10.1016/j.ypmed.2022.107169

Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).

Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.

Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi:  10.1016/j.ypmed.2022.107169

Key clinical point: Select chemopreventive agents may effectively decrease the incidence of precursor colorectal adenomas, thus lowering the future burden of colorectal cancer (CRC).

Major finding: Compared with placebo, difluoromethylornithine plus sulindac led to the highest risk reduction (76%; relative risk [RR] 0.24; 95% credible intervals [CrI] 0.10-0.55), whereas despite comparable point estimates on the recurrence of any adenomas, celecoxib (RR 0.71; 95% CrI 0.49-1.05) and aspirin (RR 0.77; 95% CrI 0.59-1.00) led to a nonsignificant risk reduction.

Study details: This network meta-analysis included 33 randomized controlled trials, with the network comprising 12 interventions plus a placebo arm, including 20,925 patients at an increased risk for CRC who had previously undergone resection of an adenoma.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Heer E et al. The efficacy of chemopreventive agents on the incidence of colorectal adenomas: A systematic review and network meta-analysis. Prev Med. 2022;162:107169 (Jul 22). Doi:  10.1016/j.ypmed.2022.107169

Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.

Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).

Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).

Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.

Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7

Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.

Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).

Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).

Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.

Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7

Key clinical point: First-line bevacizumab (BEV) is more effective than cetuximab or panitumumab (CET/PAN) against right-sided RAS wild-type (WT) metastatic colorectal cancer (mCRC), but comparably effective against left-sided RAS WT mCRC.

Major finding: Patients who received BEV vs CET/PAN had a significantly longer overall survival (hazard ratio [HR] 0.52; 95% CI 0.28-0.96) in the right-sided group, but similar overall survival in the left-sided group (HR 0.78; 95% CI 0.58-1.07).

Study details: This real-world multicenter retrospective study propensity score-matched patients with right-sided (n = 110) and left-sided (n = 450) RAS WT mCRC who received first-line treatment with BEV or CET/PAN plus fluoropyrimidine-based doublet chemotherapy (oxaliplatin or irinotecan).

Disclosures: The study received no specific funding. Some authors declared receiving grants, personal fees, honoraria for lecture and advisory roles, or research funding from various sources.

Source: Ito T et al. Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: A multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum. Int J Clin Oncol. 2022 (Jul 21). Doi: 10.1007/s10147-022-02208-7

Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.

Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P  =  .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P  =  .673).

Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002

Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.

Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P  =  .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P  =  .673).

Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002

Key clinical point: Postoperative additive chemotherapy does not increase the rate of second cancer development in patients with Union for International Cancer Control (UICC)-stage III/IV colon cancer.

Major finding: The 5-year cumulative rates for the development of a subsequent second cancer were not significantly different in patients who received vs did not receive additive chemotherapy (8.8% vs 9.0%; hazard ratio [HR] 0.944; P  =  .685), with the findings being similar even after adjusting for further risk factors (adjusted HR 1.066; P  =  .673).

Study details: This retrospective study included 2856 patients with UICC-stage III/IV colon cancer, of which 1520 patients received additive chemotherapy after R0 resection of the primary tumor and metastatic lesions.

Disclosures: The study received no funding. The authors declared no conflicts of interest.

Source: Teufel A et al. Second cancer after additive chemotherapy in patients with colon cancer. Clin Colorectal Cancer. 2022 (Jul 15). Doi: 10.1016/j.clcc.2022.07.002